Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00743288 · OUTCOME

MTD

Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma · Source last updated 2014-05-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
mg/kg melphalan
Interval / dispersion
Not reported
Time frame
12 months

What was measured

Phase 1: to determine MTD of melphalan in combination with panobinostat to be used in the Phase 2 portion of the study

Groups in this outcome

Melphalan and Panobinostat Schedule D3

20mg daily LBH589 and 0.05mg/kg melphalan on days 1, 3 and 5 of week 1

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Melphalan and Panobinostat Schedule D36

Reported measurements

Source class 1
Values in mg/kg melphalan · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Melphalan and Panobinostat Schedule D30.05Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0.05
denoms
  1. counts
    1. group Id
      OG000
      value
      6
    units
    Participants
description
Phase 1: to determine MTD of melphalan in combination with panobinostat to be used in the Phase 2 portion of the study
groups
  1. description
    20mg daily LBH589 and 0.05mg/kg melphalan on days 1, 3 and 5 of week 1
    id
    OG000
    title
    Melphalan and Panobinostat Schedule D3
param Type
NUMBER
reporting Status
POSTED
time Frame
12 months
title
MTD
type
PRIMARY
unit Of Measure
mg/kg melphalan

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice